Clinical trial
Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma…
NCT00331526 · Hoag Memorial Hospital Presbyterian, Other · Completed
Key facts
| NCT number | NCT00331526 |
|---|---|
| Title | Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme |
| Official title | Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes |
| Lead sponsor | Hoag Memorial Hospital Presbyterian, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Procedure |
| Interventions | aldesleukin, therapeutic autologous lymphocytes, adjuvant therapy, conventional surgery |
| Enrollment | 83 |
| Start date | Feb 1, 1999 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2012 |
| First posted | May 31, 2006 |
| Last update posted | Mar 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: